- Home
- CANF vs DKI Comparison
CANF vs DKI Comparison
Compare CANF & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CANF | DKI |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | Israel | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 5.9M |
| IPO Year | 2011 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CANF | DKI |
|---|---|---|
| Price | $2.25 | $2.70 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 198.3K | 30.1K |
| Earning Date | 03-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,715,455.50 | N/A |
| Revenue Next Year | $101.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.28 |
| 52 Week High | $10.40 | $11.80 |
Technical Indicators
Market Signals| Indicator | CANF | DKI |
|---|---|---|
| Relative Strength Index (RSI) | 32.90 | 36.07 |
| Support Level | $2.16 | $0.33 |
| Resistance Level | $2.39 | $5.20 |
| Average True Range (ATR) | 0.12 | 0.24 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 7.96 | 35.29 |
Price Performance
Historical ComparisonAbout CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
About DKI DarkIris Inc. Class A Ordinary Shares
Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.